PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBOncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors. More news. Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.
Evive Biotech and Acrotech Biopharma Announce FDA
WEBNov 23, 2023 · – Ryzneuta ® is the first non-pegylated granulocyte colony-stimulating factor approved by both the US Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for treatment for CIN – Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid …
Principia Presents Phase 1 Data of PRN1371 in Patients with …
WEBMay 21, 2019 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
RION Announces Initiation of Phase 2A Clinical Study for Purified ...
WEBJan 31, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 ...
WEBMar 19, 2024 · A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis; Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries
Zealand Pharma announces positive topline results from 13-week …
WEBSep 10, 2024 · Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses; Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies
Precision BioSciences Announces Investigational New Drug …
WEBAug 9, 2024 · – Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA. DURHAM, NC, USA I August 09, 2024 I Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene …
Three-year Phase 1 Follow-Up Data for mRNA-based …
WEBApr 8, 2024 · Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”)
The race of Keytruda biosimilar antibodies has begun
WEBJul 28, 2024 · In 2023, Keytruda posted global sales of US$ 25 bln which are already far higher than peak sales of anti-TNF antibody Humira in 2022 (US$ 21.6 bln) before declining to US$ 14.6 bln in 2023 due to biosimilar competition. No wonder, that the Keytruda biosimilar antibody pipeline has begun to grow and now already has more than eight …
European Commission approves Roche’s Vabysmo for treatment …
WEBJul 30, 2024 · Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal drying with Vabysmo